Novartis’ Serelaxin Poised For Standard FDA Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite the fact that Novartis’ serelaxin has been granted breakthrough therapy designation from FDA, the heart failure candidate will receive a standard 12-month review, management said during a second quarter sales and earnings call.